Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement




Feb
22
Today In Oncology
FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma
Survival Outcomes With or Without Bilateral Risk-Reducing Mastectomy in BRCA1/BRCA2 Pathogenic Variant Carriers
CLL/SLL FDA Approves Combination of Acalabrutinib and Venetoclax
Metastasis-Directed Therapy in Oligometastatic Prostate Cancer
AI Tool Classifies Pediatric Brain Tumors via Liquid Biopsy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo